Overview

Oral Administration of DCI to Women With PCOS

Status:
Terminated

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

To determine if oral DCI administration to women with PCOS increases the total DCI content in urine and blood, and, if so, if that change is accompanied by i) an increase in DCI-IPG release in blood (as determined by bioactivity) during an oral glucose challenge and ii) an increase in whole-body insulin sensitivity.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Virginia Commonwealth University

Collaborator:

National Institutes of Health (NIH)